Dr. Marc Hoffman discusses results from the GOLSEEK-1 trial of golcadomide in frontline ABCL

At the 2026 ASCO Annual Meeting, Marc Hoffman, MD, of the University of Kansas Cancer Center, discusses results from the ongoing GOLSEEK-1 trial of golcadomide, a first-in-class oral cereblon E3 ligase modulator (CELMoD), plus Pola-RCHP in first-line aggressive B-cell lymphoma.